MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges. (2024)

First Author: Phoolchund AGS
Attributed to:  Targeting natural killer cell receptors for immunotherapeutic benefit funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3390/cancers16020259

PubMed Identifier: 38254750

Publication URI: http://europepmc.org/abstract/MED/38254750

Type: Journal Article/Review

Volume: 16

Parent Publication: Cancers

Issue: 2

ISSN: 2072-6694